Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data

Italian Heart Journal

Volumn 5, Issue 2, 2004, Pages 120-126

  Esposti, Luca Degli ^a   di Martino, Mirko ^a   Saragoni, Stefania ^a   Valpiani, Giorgia ^a   Capone, Alessandro ^a   Corvi, Elena ^b   Esposti, Ezio Degli ^b  

^a Economics and Outcomes Research   (Italy)

^b Local Health Unit   (Italy)

Author keywords

Clinical database; Costs; Myocardial infarction; Outpatient management; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; COST; DOSE RESPONSE; DRUG THERAPY; ECONOMICS; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; ITALY; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COST ALLOCATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; TREATMENT OUTCOME;

EID: 4644306151     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. N Engl J Med 1996; 335: 1001-9.
3. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
5. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998; 279: 1458-62.
6. Jackevicius CA, Mamdani M, Tu JV. Adherence to statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-7.
7. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
8. Applegate WB. Elderly patients' adherence to statin therapy. JAMA 2002; 288: 495-7.
9. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-82.
10. EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
11. Black N. Developing high quality clinical databases. BMJ 1997; 315: 381-2.
12. Black N, Payne M. Improving the use of clinical databases. BMJ 2002; 324: 1194.
13. Black N. High-quality clinical databases: breaking down barriers. Lancet 1999; 353: 1205-6.
14. Relman AS. Assessment and accountability. The third revolution in medical care. N Engl J Med 1998; 319: 1220-2.
15. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med 1996; 124: 832-7.
16. Anatomical-Therapeutic-Chemical Classification of Drugs. Milano: Organizzazione Editoriale Medico-Farmaceutica, 1999.
17. International Classification of Diseases. 9th version. Geneva: World Health Organization, 1977.
18. Istituto Nazionale di Statistica (ISTAT). Servizio delle statistiche dei prezzi. http://www.istat.it/Economia/Prezzi/index.htm
19. Armitage P, Berry G. Statistica medica. Metodi statistici per la ricerca in medicina. Milano: McGraw-Hill Libri Italia, 1996.
20. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction. Arch Intern Med 2001; 161: 183-8.
21. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in use of cholesterol-lowering agents in older adults. Arch Intern Med 1998; 158: 1761-8.
22. Baxter C, Jones R, Corr L. Time trends analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: 1134-5.
23. Degli Esposti L, Valpiani G, Baio G. Valutare l'efficacia degli interventi in sanita. Guida alla raccolta ed alla gestione dei dati clinici ed amministrativi. Roma: Il Pensiero Scientifico Editore, 2002.
24. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcome research and pharmacoeconomic analyses. Pharmacoeconomics 1999; 16: 1-8.
25. Motheral BR, Fairman KA. The use of claims databases for outcome research: rational challenges and strategies. Clin Ther 1997; 19: 346-66.
26. Black N. Why do we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-8.
27. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Pharmacoeconomics 1999; 15: 423-34.